ETOPOSIDE

Post-LOE

etoposide

Entera Bio

ANDAINJECTIONINJECTABLE

Approved

Jun 1995

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ETOPOSIDE (etoposide) by Entera Bio is dna-topoisomerase ii or the formation of free radicals, leading to cell cycle arrest, primarily at the g2 stage of the cell cycle, and cell death. Approved for refractory testicular cancer in adult patients, lung cancer, lung cancer. First approved in 1995.

Drug data last refreshed 18h ago

Mechanism of Action

DNA-topoisomerase II or the formation of free radicals, leading to cell cycle arrest, primarily at the G2 stage of the cell cycle, and cell death.

Indications (2)

refractory testicular cancer in adult patients lung cancer

Clinical Trials (20)

NCT07544654Phase 3Not Yet Recruiting

DAREON-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Started Jun 2026

390 enrolled

Extrapulmonary Neuroendocrine Cancer

NCT06738368Phase 2Recruiting

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Started May 2026

30 enrolled

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeT Acute Lymphoblastic Leukemia

NCT07449481Phase 2Not Yet Recruiting

A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

Started May 2026

56 enrolled

Malignant Solid TumorBrain Metastasis

NCT07472517Phase 3Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Started Apr 2026

670 enrolled

Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)

NCT07097363Phase 2Recruiting

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Started Dec 2025

18 enrolled

B-Cell Non-Hodgkin LymphomaBurkitt LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more

Worked on ETOPOSIDE at Entera Bio? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.